ABS Side-branch Access Stenting System (ABS MD-SBA)
Coronary Bifurcation Lesions (Percutaneous Coronary Intervention)
FDA Breakthrough Device DesignationClinical Development (First-in-Human Trial Completed)
Key Facts
Indication
Coronary Bifurcation Lesions (Percutaneous Coronary Intervention)
Phase
FDA Breakthrough Device Designation
Status
Clinical Development (First-in-Human Trial Completed)
Company
About Advanced Bifurcation Systems
Advanced Bifurcation Systems is pioneering a transformative solution for coronary artery disease, specifically targeting bifurcation lesions where plaque blockages occur at vessel branches. With over 75 issued patents and FDA Breakthrough Device Designation, its proprietary platform enables precise, safe, and efficient stent placement, making advanced bifurcation stenting accessible to a broader range of interventional cardiologists. The company is positioned to address a significant unmet need in cardiovascular care, potentially reducing the need for open-heart surgery and optimizing hospital resource utilization.
View full company profileTherapeutic Areas
Other Coronary Bifurcation Lesions (Percutaneous Coronary Intervention) Drugs
| Drug | Company | Phase |
|---|---|---|
| ABS Two Stent System (ABS MD-BI) | Advanced Bifurcation Systems | Pre-Clinical |